QUINCE THERAPEUTICS INC (QNCX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$31.32+2.52%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · QNCX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
QNCX — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-09-04
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 31, 2026, Quince Therapeutics, Inc. (the “Company”) received a written notification (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, the Company’s stockholders’ equity was ($35,324,000), and therefore, the Company was not…
Why it matters: Meeting listing rules is key for Quince. It helps the company operate and attract investors.
Worry ifManagement has a clear plan and timeline to meet Nasdaq listing rules.
Less concerning ifThe company is not meeting Nasdaq standards. There are also no updates from management.
Why it matters: Updates on cash runway will indicate if Quince can fund operations through 2028 as planned.
Watch forManagement says they have enough cash until the end of 2028 after the buy.
Also watch forManagement says cash runway is shorter than expected. This raises concerns about funding.
Why it matters: Reviewing options may lead to new deals or partnerships that help growth.
Watch forLook for news about a new deal or partnership from the review.
Also watch forWatch for news that the review of options is canceled without a clear plan.
Why it matters: Starting the SAPH trial would show commitment to expanding LAM-001's use. Delays could raise concerns about execution.
Supportive ifPhase 2 trial of LAM-001 in SAPH is anticipated to begin in late 2026.
Worry ifNo announcement of trial initiation by the end of 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$283 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $1,056 loss on $10,000 · 10.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,818 loss on $10,000 · 98.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The timing of this split is crucial for compliance with Nasdaq listing rules.
Watch forThe reverse stock split is implemented within the next few months.
Also watch forNo action is taken on the reverse stock split by the end of 2026.
Why it matters: Approval is needed to meet Nasdaq rules and help the stock price.
Worry ifStockholders approve the reverse stock split at the upcoming meeting.
Less concerning ifStockholders reject the reverse stock split proposal.
Why it matters: This acquisition is key for growth and could change the company's future. If completed, it may boost investor confidence.
Supportive ifLook for news that Orphai Entities are now part of QNCX.
Worry ifWatch for news about delays or problems with the Orphai Entities integration.
Why it matters: Starting this trial is crucial for advancing LAM-001 and could impact future funding and partnerships.
Supportive ifThe Phase 2b trial of LAM-001 in PH-ILD is initiated as planned.
Worry ifThe Phase 2b trial of LAM-001 in PH-ILD is postponed or canceled.
Why it matters: Data from this trial could show LAM-001 works well and help its development.
Supportive ifTopline data from the Phase 2 trial of LAM-001 in BOS is released in Q1 2027.
Worry ifData from the Phase 2 trial of LAM-001 in BOS is delayed beyond Q1 2027.